Earlier Monday, the Federal Circuit ordered the Patent Trial and Appeal Board to re-consider two inter partes review petitions that had been brought by Axonics (AXNX) against Medtronic (MDT) patents, Wells Fargo analyst Larry Biegelsen. The firm’s patent consultant views this as a positive update for Axonics. The news today means that, whenever those other two IPRs finish, the court might continue the stay in order to wait for the two that were remanded today, says Wells. It believes Axonics “continues to gain ground.” The company has “put together an impressive set of wins in the various appeals and has meaningfully improved its overall positioning in the case,” writes Wells.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AXNX:
- Wells says Axonics’ position ‘meaningfully improved’ with IPRs sent back to PTAB
- Axonics price target raised to $76 from $73 at Needham
- Axonics price target raised to $70 from $69 at Baird
- Axonics price target raised to $71 from $70 at KeyBanc
- Axonics raises FY23 revenue view to $358M from $348M, consensus $348.93M